A research study of a new medicine NNC0519-0130 in Japanese and non-Japanese men

Completed

Recruitment & Eligibility

Inclusion Criteria

Body mass index (BMI) between 23.0 kg/m2 and 39.9 kg/m2 (both inclusive) at screening with a minimum weight of 50 kg. Overweight should be due to excess adipose tissue, as judged by the investigator.
Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion Criteria

Any disorder, which in the investigator opinion might jeopardise safety of participant or compliance with the protocol.
Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, GI, or endocrinological conditions.
HbA1c >= 6.5 % (48 mmol/mol) at screening. -Use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid (ASA), and domperidon, or topical medication not reaching systemic circulation, within 14 days before screening.

Primary Outcome Measures

Name	Time	Method
Area under the NNC0519-0130 plasma concentration-time curve after the last dose in each treatment period	after the last dose in each treatment period	Area under the NNC0519-0130 plasma concentration-time curve
Maximum plasma concentration of NNC0519-0130 after the last dose in each treatment period	after the last dose in each treatment period	Maximum plasma concentration of NNC0519-0130
Terminal half-life of NNC0519-0130 after the last dose	after the last dose	Terminal half-life of NNC0519-0130

Secondary Outcome Measures

Name	Time	Method